Citation: | MA Zhong-hui, GAO Jie, CAO Dong-dong, YANG Yue-cheng, YE Run-hua, WANG Ji-bao, TANG Ren-hai, HE Na, DING Ying-ying, DUAN Song. Prevalence and associated factors of multimorbidity among newly reported HIV-positive individuals in Dehong Dai and Jingpo Autonomous Prefecture[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(12): 1380-1386. doi: 10.16462/j.cnki.zhjbkz.2021.12.004 |
[1] |
Trickey A, May MT, Vehreschild JJ, et al. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies[J]. Lancet HIV, 2017, 4(8): e349-e356. DOI: 10.1016/s2352-3018(17)30066-8.
|
[2] |
Gueler A, Moser A, Calmy A, et al. Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population[J]. AIDS, 2017, 31(3): 427-436. DOI: 10.1097/qad.0000000000001335.
|
[3] |
Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada[J]. PLoS One, 2013, 8(12): e81355. DOI: 10.1371/journal.pone.0081355.
|
[4] |
Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population[J]. Clin Infect Dis, 2011, 53(11): 1120-1126. DOI: 10.1093/cid/cir627.
|
[5] |
Pathai S, Bajillan H, Landay AL, et al. Is HIV a model of accelerated or accentuated aging?[J]. J Gerontol A Biol Sci Med Sci, 2014, 69(7): 833-842. DOI: 10.1093/gerona/glt168.
|
[6] |
Althoff KN, Smit M, Reiss P, et al. HIV and ageing: improving quantity and quality of life[J]. Curr Opin HIV AIDS, 2016, 11(5): 527-536. DOI: 10.1097/coh.0000000000000305.
|
[7] |
Thienemann F, Sliwa K, Rockstroh JK. HIV and the heart: the impact of antiretroviral therapy: a global perspective[J]. Eur Heart J, 2013, 34(46): 3538-3546. DOI: 10.1093/eurheartj/eht388.
|
[8] |
Non LR, Escota GV, Powderly WG. HIV and its relationship to insulin resistance and lipid abnormalities[J]. Transl Res, 2017, 183: 41-56. DOI: 10.1016/j.trsl.2016.12.007.
|
[9] |
Schank M, Zhao J, Moorman JP, et al. The impact of HIV- and ART-induced mitochondrial dysfunction in cellular senescence and aging[J]. Cells, 2021, 10(1): 174. DOI: 10.3390/cells10010174.
|
[10] |
Lagathu C, Bereziat V, Gorwood J, et al. Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment[J]. Expert Opin Drug Saf, 2019, 18(9): 829-840. DOI: 10.1080/14740338.2019.1644317.
|
[11] |
Kingery JR, Alfred Y, Smart LR, et al. Short-term and long-term cardiovascular risk, metabolic syndrome and HIV in Tanzania[J]. Heart, 2016, 102(15): 1200-1205. DOI: 10.1136/heartjnl-2015-309026.
|
[12] |
Nduka CU, Stranges S, Kimani PK, et al. Is there sufficient evidence for a causal association between antiretroviral therapy and diabetes in HIV-infected patients? A meta-analysis[J]. Diabetes Metab Res Rev, 2017, 33(6). DOI: 10.1002/dmrr.2902.
|
[13] |
Back D, Marzolini C. The challenge of HIV treatment in an era of polypharmacy[J]. J Int AIDS Soc, 2020, 23(2): e25449. DOI: 10.1002/jia2.25449.
|
[14] |
中国高血压防治指南修订委员会. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志, 2019, 24(1): 24-56. DOI: 10.3969/j.issn.1007-5410.2019.01.002.
Writing Group of Chinese Guidelines for the Management of Hypertension. 2018 Chinese guidelines for the management of hypertension[J]. Chin J Cardiovasc Med, 2019, 24(1): 24-56. DOI: 10.3969/j.issn.1007-5410.2019.01.002.
|
[15] |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4): 315-409. DOI: 10.3760/cma.j.cn115791-20210221-00095.
Chinese Diabetes Society. Guidelines for the prevention and control of type 2 diabetes in China (2020 Edition)[J]. Chin J Diabetes Mellitus, 2021, 13(4): 315-409. DOI: 10.3760/cma.j.cn115791-20210221-00095.
|
[16] |
中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 血脂异常基层诊疗指南(2019年)[J]. 中华全科医师杂志, 2019, 18(5): 406-416. DOI: 10.3760/cma.j.issn.1671-7368.2019.05.003.
Chinese Medical Association, Chinese Medical Journals Publishing House, Chinese Society of General Practice, et al. Guideline for primary care of dysliplidemias (2019)[J]. Chin J Gen Pract, 2019, 18(5): 406-416. DOI: 10.3760/cma.j.issn.1671-7368.2019.05.003.
|
[17] |
中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 中华传染病杂志, 2020, 38(1): 9-28. DOI: 10.3760/cma.j.issn.1000-6680.2020.01.004.
Chinese Society of Hepatology, Chinese Society of Infectious Diseases. Guidelines for the prevention and treatment of hepatitis C (2019 version)[J]. Chin J Infect Dis, 2020, 38(1): 9-28. DOI: 10.3760/cma.j.issn.1000-6680.2020.01.004.
|
[18] |
Shen YZ, Wang ZY, Lu HZ, et al. Prevalence of anemia among adults with newly diagnosed HIV/AIDS in China[J]. PLoS One, 2013, 8(9): e73807. DOI: 10.1371/journal.pone.0073807.
|
[19] |
Zhang LX, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818): 815-822. DOI: 10.1016/s0140-6736(12)60033-6.
|
[20] |
上海慢性肾脏病早发现及规范化诊治与示范项目专家组. 慢性肾脏病筛查诊断及防治指南[J]. 中国实用内科杂志, 2017, 37(1): 28-34. DOI: 10.19538/j.nk2017010108.
Shanghai Expert Group of Early Detection, Standardized Diagnosis, Treatment and Demonstration Project of Chronic Kidney Disease. Guidelines for screening, diagnosis and prevention of chronic kidney disease[J]. Chin J Pract Intern Med, 2017, 37(1): 28-34. DOI: 10.19538/j.nk2017010108.
|
[21] |
Chen R, Chen J, Tang Q, et al. Use of comedications and potential drug -drug interactions in people living with HIV in China[J]. J Infection Chemother, 2020, 26(7): 722-728. DOI: 10.1016/j.jiac.2020.04.003.
|
[22] |
Schouten J, Wit FW, Stolte IG, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study[J]. Clin Infect Dis, 2014, 59(12): 1787-1797. DOI: 10.1093/cid/ciu701.
|
[23] |
Lin L, Li TS. Multidisciplinary collaborative integrated management of increasingly prominent HIV complications in the post-cART era[J]. HIV Med, 2020, 21(11): 683-691. DOI: 10.1111/hiv.13022.
|
[24] |
Abebe F, Schneider M, Asrat B, et al. Multimorbidity of chronic non-communicable diseases in low- and middle-income countries: a scoping review[J]. J Comorb, 2020, 10: 2235042x20961919. DOI: 10.1177/2235042x20961919.
|
[25] |
Pacheco YM, Jarrin I, Rosado I, et al. Increased risk of non-AIDS-related events in HIV subjects with persistent low CD4 counts despite cART in the CoRIS cohort[J]. Antiviral Research, 2015, 117: 69-74. DOI: 10.1016/j.antiviral.2015.03.002.
|
[26] |
徐小慧, 单淑晴, 时允, 等. 云南省德宏州接受抗病毒治疗的HIV感染者高血压患病率及其影响因素[J]. 中国初级卫生保健, 2020, 34(4): 48-51. DOI: 10.3969/j.issn.1001-568x.2020.04.0015.
Xu XH, Shan SQ, Shi Y, et al. Prevalence and associated factors of hypertension among HIV-infected individuals receiving combination antiretroviral therapy in Dehong Prefecture, Yunnan Province[J]. Chin Primary Health Care, 2020, 34(4): 48-51. DOI: 10.3969/j.issn.1001-568x.2020.04.0015.
|
[27] |
叶润华, 李静, 姚仕堂, 等. 德宏傣族景颇族自治州抗病毒治疗的HIV/AIDS糖尿病患病率及其相关因素分析[J]. 中华流行病学杂志, 2019, 40(6): 654-659. DOI: 10.3760/cma.j.issn.0254-6450.2019.06.010.
Ye RH, Li J, Yao ST, et al. Prevalence and related factors on diabetes among HIV/AIDS receiving antiretroviral therapy in Dehong Dai and Jingpo Autonomous Prefecture[J]. Chin J Epidemiol, 2019, 40(6): 654-659. DOI: 10.3760/cma.j.issn.0254-6450.2019.06.010.
|
[28] |
姚仕堂, 何春燕, 曹东冬, 等. 德宏傣族景颇族自治州2010-2019年HIV感染者抗病毒治疗后艾滋病和非艾滋病相关死亡及其影响因素分析[J]. 中华流行病学杂志, 2021, 42(4): 632-637. DOI: 10.3760/cma.j.cn112338-20200903-01121.
Yao ST, He CY, Cao DD, et al. Incidence and influencing factors of AIDS-related and non-AIDS-related deaths after receiving antiretroviral therapy among HIV-positive individuals in Dehong Dai and Jingpo Autonomous Prefecture, 2010-2019[J]. Chin J Epidemiol, 2021, 42(4): 632-637. DOI: 10.3760/cma.j.cn112338-20200903-01121.
|
[29] |
王继宝, 陈晓晨, 段星, 等. 云南省德宏州2016-2017年新报告中国和缅甸籍HIV感染者中HCV的流行病学特征[J]. 中华疾病控制杂志, 2019, 23(10): 1293-1296, 1300. DOI: 10.16462/j.cnki.zhjbkz.2019.10.026.
Wang JB, Chen XC, Duan X, et al. Epidemiological characteristics of co-infection of hepatitis C virus among newly reported HIV infected patients in Chinese and Burmese from 2016 to 2017 in Dehong Prefecture of Yunnan Province[J]. Chin J Dis Control Prev, 2019, 23(10): 1293-1296, 1300. DOI: 10.16462/j.cnki.zhjbkz.2019.10.026.
|
[30] |
Shen Y, Wang J, Wang Z, et al. Prevalence of dyslipidemia among antiretroviral-naive HIV-infected individuals in China[J]. Medicine, 2015, 94(48): e2201. DOI: 10.1097/md.0000000000002201.
|
[31] |
De FD, Verboeket SO, Underwood J, et al. Patterns of co-occurring comorbidities in people living with HIV[J]. Open Forum Infect Dis, 2018, 5(11): ofy272. DOI: 10.1093/ofid/ofy272.
|
[32] |
Yang X, Zhang J, Chen S, et al. Comorbidity patterns among people living with HIV: a hierarchical clustering approach through integrated electronic health records data in South Carolina[J]. AIDS Care, 2021, 33(5): 594-606. DOI: 10.1080/09540121.2020.1844864.
|